Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels

Laboratory Medicine

Volumn 41, Issue 3, 2010, Pages 159-163

  Stanilov, Noyko ^a   Miteva, Lyuba ^b   Deliysky, Tashko ^c   Jovchev, Jovcho ^a   Stanilova, Spaska ^b  

^a University Hospital   (Bulgaria)

^b TRAKIA UNIVERSITY   (Bulgaria)

^c MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER IMMUNOLOGY; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; QUANTITATIVE ANALYSIS; SERUM;

EID: 77951971709     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LM7T43AQZIUPIOWZ     Document Type: Article

References (36)

1. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
2. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22.
3. Dalerba P, Maccalli C, Casati C, et al. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol. 2003;46:33-57.
4. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol. 1995;13:251-256.
5. Brunda MJ, Luistro L, Hendrzak JA, et al. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother. 1995;17:71-77.
6. Gri G, Chiodoni C, Gallo E, et al. Antitumor effect of Interleukin (IL)-12 in the absence of endogeneous IFN-g: A role for intrinsic tumor immunogenicity and IL-15. Cancer Res. 2002;62:4390-4397. (Pubitemid 34827298)
7. Oppmann B, Lesley R, Blom B, et l. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
8. Lankford RSC, Fricht MD. A unique role for IL-23 in promoting cellular immunity. J Leukoc Biol. 2003;73:49-56.
9. Numasaki M, Fukushi J, Ono M, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101:2620-2627. (Pubitemid 36857622)
10. Takahashi H, Numasaki M, Lotze MT, et al. Interleukin-17 enhances bFGF, HGF, and VEGF-induced growth of vascular endothelial cells. Immunol Lett. 2005;98:189-193. (Pubitemid 40602629)
11. Kawamura K, Bahar R, Natsume W, et al. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity against tumors. Cancer Gene Ther. 2002;9:109-115. (Pubitemid 34052860)
12. O'Hara RJ, Greenman J, MacDonald AW, et al. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res. 1998;4:1943-1948. (Pubitemid 28369179)
13. Mocellin S, Maricola FM, Young HA. Interleukin-10 and the immune response against cancer: A counterpoint. J Leukoc Biol. 2004;78:1043-1051.
14. Mocellin S, Panelli MC, Wang E, et al. The dual role of IL-10. Trends Immunol. 2003;24:36-43.
15. Biron CA. Interferons alpha and beta as immune regulators - A new look. Immunity. 2001;14:661-664.
16. Jonasch E, Haluska F. Interferon in oncological practice: Review of interferon biology, clinical application, and toxicities. Oncologist. 2001;6:34-55. (Pubitemid 32155814)
17. Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology. 2003;50:1009-1012.
18. Becker C, Fantini MC, Wirtz S, et al. IL-6 signaling promotes tumor growth in colorectal cancer. Cell Cycle. 2005;4:217-220. (Pubitemid 41365319)
19. Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175-1183. (Pubitemid 46718402)
20. Wang YQ, Ugai S, Shimozato O, et al. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer. 2003;105:820-824. (Pubitemid 36706106)
21. Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003;171:600-607.
22. Shan B, Hao J, Li Q, et al. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell Mol Immunol. 2006;3:47-52.
23. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumor incidence and growth. Nature. 2006;442:461-465. (Pubitemid 44264796)
24. Stanilov N, Miteva L, Mintchev N, et al. High expression of Foxp3, IL-23p19 and survivin mRNA in colorectal carcinoma. Int J Colorectal Dis. DOI: 10.1007/s00384-008-0588-8, 2008.
25. Weaver C, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821-852. (Pubitemid 46697925)
26. Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-kB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. 2006;176:5652-5661.
27. Schwartz S, Beaulieu JF, Ruemmele FM. Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth. Biochem Biophys Res Commun. 2005;337:505-509. (Pubitemid 41429313)
28. Numasaki M, Watanabe M, Suzuki T, et al. Interleukin-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175:6177-6189. (Pubitemid 41508106)
29. Wagsater D, Lofgren S, Hugander A, et al. Expression of Interleukin-17 in human colorectal cancer. Anticancer Res. 2006;26:4213-4216. (Pubitemid 46031493)
30. Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw. 2006;17:60-66.
31. Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12, and 18 levels in patients with head and neck cancer. J Laryngol Otol. 2007;121:246-252. (Pubitemid 46833125)
32. Mustea A, Könsgen D, Braicu EI, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res. 2006;26:1715-1818.
33. Fortis C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 1996;104:1-5. (Pubitemid 26154004)
34. Gianotti L, Fortis C, Braga M, et al. Radical oncologic surgery affects the circulatory levels of interleukin 10. J Surg Oncol. 1997;66:244-247. (Pubitemid 28013698)
35. Galizia G, Orditura M, Romano C, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol. 2002;102:169-178. (Pubitemid 34171516)
36. Yang JL, Qu XJ, Russell PJ, et al. Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines. Oncology. 2005;69:224-238. (Pubitemid 41433581)